Celsentri® — Competitive Intelligence Brief

Celsentri® (Celsentri®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CCR5 antagonist. Area: Infectious Disease.

phase 3 CCR5 antagonist CCR5 Infectious Disease Small molecule

Target snapshot

Celsentri® (Celsentri®) — Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer. Celsentri is a CCR5 antagonist that blocks the CCR5 co-receptor on CD4+ T cells, preventing HIV entry and infection.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Celsentri® TARGET	Celsentri®	Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer	phase 3	CCR5 antagonist	CCR5
Sirolimus + Maraviroc	Sirolimus + Maraviroc	University of Maryland, Baltimore	marketed	mTOR inhibitor + CCR5 antagonist combination	mTOR; CCR5
Maraviroc (MVC)	Maraviroc (MVC)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	CCR5 antagonist	CCR5 (C-C chemokine receptor type 5)
emtricitabine, darunavir/cobicistat, maraviroc	emtricitabine, darunavir/cobicistat, maraviroc	Giovanni Di Perri	marketed	Antiretroviral combination (NRTI + PI + pharmacokinetic booster + CCR5 antagonist)	HIV reverse transcriptase, HIV protease, CYP3A4, CCR5 co-receptor
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor
Antiretroviral/Anti HIV	Antiretroviral/Anti HIV	MSD Pharmaceuticals LLC	marketed	Antiretroviral agent (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitor)	HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, or CXCR4 (depending on specific agent)
HIV therapy	HIV therapy	ViiV Healthcare	marketed	Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors)	Multiple targets depending on specific agent (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5 co-receptor, gp120/gp41 envelope proteins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CCR5 antagonist class)

1. ANRS, Emerging Infectious Diseases · 1 drug in this class
2. Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · 1 drug in this class
3. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
4. Theratechnologies · 1 drug in this class